EGFR and non-small cell lung carcinoma: The present study therefore aimed to address these critical gaps in our understanding of first-line osimertinib-induced ILD in EGFR-mutated NSCLC though investigating the ILD incidence, efficacy and safety of treatments administered after osimertinib discontinuation, prognosis of patients with ILD development during osimertinib therapy, and resumption of osimertinib therapy after ILD onset.